Mar 14, 2023 / 06:35PM GMT
Luke England Sergott - Barclays Bank PLC, Research Division - Research Analyst
All right. Good afternoon, everybody. I'm Luke Sergott. I cover life sciences tools and diagnostics here at Barclays. It's my pleasure to have with me Jim Hippel from CFO of Bio-Techne. It's been a long time. We're just commenting it's about 3 years for you. I'm glad to have you back.
Questions and Answers:
Luke England Sergott - Barclays Bank PLC, Research Division - Research AnalystTo kick it off, let's start off just like real high-level thoughts of what you saw coming out of your quarter. The underlying market demand going into your guidance and -- we can start there and then dig in further.
James T. Hippel - Bio-Techne Corporation - Executive VP of Finance & CFO
Sure. I think I'll start on a positive note, which is that our underlying demand and the health of our end markets, we believe, are still very strong. And despite this print, what makes me say that is in the last few years of COVID noise, you got to dig a little